Advisory Council Members
Partner, National Health Consulting Leader at Deloitte
Lisa Purdy is a Partner at Deloitte and she leads the Canadian National Health Services Practice. For over 20 years, Lisa has worked with individual providers, regional systems, and provincial health organizations and agencies in addressing their strategic, governance, operations, and technology solution requirements. Through her work within the health sector, Lisa has developed an understanding of health system issues, hospital operations, stakeholder perspectives, and overarching system governance, business, and technology management considerations.
Throughout her career, Lisa has been involved in numerous system design projects. She has led complex stakeholder engagements with physicians, clinicians, other practitioners, and administrators, and has been instrumental in guiding organizations through complicated operational changes. She has worked with clients to evaluate alternative models and move forward with a preferred direction to improve both the efficiency and quality of services provided, as well as developed effective business cases for the future state. Lisa also brings extensive experience working with clients to identify opportunities for operational efficiencies through integrated models and shared services.
Lisa contributes her leadership to various advisory boards, including the Ivey International Centre for Health Innovation and the Conference Board of Canada’s Canadian Alliance for Sustainable Health Care.
Owner and Operator, P-A-K Limited
Paul has over 30 years of experience in alternative investments, business development, corporate strategy and advisory roles gained in the USA, Canada, and Europe. He owns and operates P-A-K Limited, a private advisory firm establish is 2006.
Clients include Le Fonds de Solidarite –FTQ, the Centre for the Commercialization of Regenerative Medicine, and XOR Laboratories. He also has advised the Kirchner Group and other PE/VC firms.
Previously, he was the Executive Vice President of the Business Development Bank of Canada, responsible for its Venture Capital business (BDC VC). BDC VC has over $1 billion in current and planned investments in both direct investing into technology based companies and Indirect fund of funds investing into technology focused funds. Prior to that, he was the Managing Director of Healthcare Funds for Drug Royalty Corporation (now DRI Capital) which deployed approximately $1 billion in royalty acquisitions with excellent returns. He also has held the global Business Development position for the world’s largest vaccine company, Aventis Pasteur, as well as having lead the corporate equity function at the 3rd largest pharmaceutical company, Aventis Capital, a subsidiary of Aventis SA.
He serves as Vice Chairman on the Advisory Council of the International Centre for Healthcare Innovation at the Ivey School of Business, Western University. He is also the Chair of the Advisory Committee of the Canadian Basketball Academy, a not-for-profit organization supporting youth in the GTA. He previously has served on the Board of Osteoporosis Canada, and of various public and private companies.
Paul has a BA from the University of Toronto where his thesis was ‘Nationalism, Technology and the Multinational Corporation’ and an MBA from the Ivey School of Business at Western University where he was awarded an academic scholarship for International Business.
Robert E. Kennedy
Dean, Ivey Business School
Lawrence G. Tapp Chair in Leadership
Bob Kennedy was appointed Dean of Ivey Business School in October 2013 and was the school’s first academic Dean since 1995.
Ivey has a long-standing reputation for strong and innovative programs. This positioning continues across all degree programs with growing applications, strong and improving rankings, and Canada’s highest placement rates and starting salaries. Dean Kennedy is also working to reaffirm Ivey’s reputation for thought leadership on issues critical to business and public policy leaders. Finally, he has introduced a new international strategy, restructuring Ivey’s programs in Asia and working to expand partnerships with other leading business schools.
Bob came to Ivey from the University of Michigan’s Ross School of Business where he led the William Davidson Institute, a research and educational institute that focuses on issues in emerging market economies. He holds degrees from Stanford University and MIT, and a Ph.D. in Business Economics from Harvard University, where he was an Assistant, and later Associate, Professor at the business school.
Neil D. Fraser
President, Medtronic Canada
Regional Vice-President – Canada, Medtronic plc
Through innovation and collaboration, Medtronic helps to improve the lives and health of millions of people each year. Neil Fraser is the President of Medtronic Canada and Regional Vice-President - Canada, Medtronic plc. He is also the Chair of MEDEC and a Board Member of Baycrest Health Sciences. In 2014, he was a member of the federal Advisory Panel on Healthcare Innovation and the Ontario Health Innovation Council. Neil is a frequent speaker on the topics of value-based procurement, outcomes-based healthcare, and the medical device sector’s role in improving clinical outcomes, economic value, and access to quality healthcare.
Managing Director, ABCLive Corporation
Mr. Garcia serves as the Managing Director for ABC Live Corporation, a global management consulting firm working with leading businesses, public sector entities, and not-for-profit organizations in the Americas, Europe, Australia and Africa. He focuses his efforts on helping clients develop strategies, plans, improve business performance, identify and capture global markets, and excel through Leadership, Innovation, Vision and Execution, particularly relating to Big Data Analytics, the Internet of Things, Cyber Security, Mobility, Health Innovation, and Communications.
Mr Garcia is an Adjunct Professor at the Schulich School of Business, York University (MBAN, Master of Analytics program), a member of the Board of Directors, Toronto 2015 PanAm/ParapanAm Games, and serves as Advisory Board member of the Schulich School of Business Analytics (York University), and the Ivey Centre for Health Innovation (University of Western Ontario). He has been a member of the Information Technology Association of Canada (ITAC) Cyber Security Council since 2006.
Mr. Garcia was a Senior Fellow at Bell Canada Enterprises, and the Chief Technology Officer for Hewlett Packard (HP) Canada, with responsibility for innovation management, emerging technologies, big data/analytics, mobility, health innovation, mobility and strategic technology partnerships. He has been identified as a subject matter expert by industry groups, universities, clients, partners and media on diverse business and technology areas. Mr. Garcia represented HP and Bell in industry groups, boards, conferences and associations world-wide, and was appointed as an advisor to the Ontario Minister of Innovation and the Ontario Minister of Economic Development and Trade.
As a senior business executive with Canadian and international experience, he has held executive management, trusted advisory positions and delivered large scale, complex projects in the Americas, Europe, Africa and Asia Pacific. He was a member of multiple Federal and Provincial Government trade missions, including two Team Canada commercial missions to Latin America led by the Prime Minister of Canada, actively participating and sponsoring activities designed to improve business relations with participating trade countries and create collaborative joint ventures involving business, universities and governments.
He was selected and recognized as one of Canada’s “Ten Most Influential Hispanic Canadians” in 2012, as one of “HP Americas” Most Valuable Players” in 2007 and nominated and selected as a finalist for the 1997 “Top 40 Under 40 Award”, a program designed to recognize the achievements of outstanding Canadians under the age of 40.
Former Vice President of Corporate Affairs, Eli Lilly Canada
Mr. D. Terry McCool was the Vice President of Corporate Affairs at Eli Lilly Canada. In this role he was responsible for all aspects of corporate affairs including federal and provincial government affairs, policy development, provincial and private reimbursement, pricing, health outcomes, advocacy relations, communications, strategic partnerships and public affairs.
Since joining Eli Lilly Canada, Mr. McCool held various senior management positions including Vice President of Sales and Vice President of Human Resources. He was also a member of the Senior Management Team and the Board of Directors of Eli Lilly Canada.
Mr. McCool sat on a number of industry association committees at the Pharmaceutical Research and Manufacturers of America (PhRMA) and Canada’s Research-Based Pharmaceutical Companies (Rx&D). He was Chair of the Intellectual Property Committee at Rx&D, and Chair of the Canada Committee at PhRMA, a Director and Member of the Executive Committee at the Institute of Health Economics in Alberta, a member of the Dean’s Advisory Committee for the University of Alberta’s Faculty of Pharmacy and a member of the Life Sciences Advisory Board for the Department of Foreign Affairs and International Trade. He also chaired the Ottawa Liaison Committee for the Chamber of Commerce in Ottawa.
Upon retirement Mr. McCool consults with Industry and Government. He is on the Board of Ontario Bioscience Innovation Organization (OBIO) and the International Center for Health Innovation at the Ivey School of Business.
Mr. McCool has a Bachelor of Science in Pharmacy from the University of Alberta and attended the Advanced Management programs at Kelley School of Business at Indiana University.
Brent H. Norton
President & CEO, Director, MedCurrent Inc.
Venture Partner, Lumira Capital
Dr. Norton is a leader in the Life Science industry with operational and Director experience across several successful enterprises which achieved significant multiples for investors. Dr. Norton founded PreMD, completing IPO’s and listings on both TSX and AMEX. Operationally, he has built R&D and commercial operations, led transactions with AstraZeneca, Atherogenics, Eli Lilly, L’Oreal, Parke Davis/Pfizer, etc., and taken products through the FDA to global out-licensing with Johnson & Johnson. He is a founding Director of Novadaq Technologies (TSX:NDQ, NASDAQ:NVDQ), one of Canada’s most valuable medical companies. Dr. Norton has been an active member of several BOD’s, public and private, in both Canada and the US. He is a Venture Partner at Lumira Capital, a member of the Research Committee for CAMH, an Advisory BOD member for the Ivey International Centre for Health Innovation, and a Past-President and Director of the Osler Bluff Ski Club and Director of Alpine Ontario.
President, Graham Scott Strategies Inc.
Graham Scott is President of Graham Scott Strategies Inc. He has extensive experience in public policy, governance and in the assessment of boards and management teams with a particular emphasis on health care.
He was Executive Assistant to the Rt. Hon. Robert Stanfield and held a number of posts in the Ontario Government including
Associate Secretary of Cabinet and Deputy Minister of Health.
Mr. Scott was a Partner at the law firm of McMillan LLP from 1984 until 2008 and served as Managing Partner from 2000-2006.
Mr. Scott represents health and government clients in matters of governance and accountability and has been involved in the amalgamation, restructuring and governance processes of more than 40 hospitals primarily working with Maureen Quigley.
In 2001-2002, Mr. Scott served as Interim President and CEO of Cancer Care Ontario. In 2003, he was appointed Supervisor of the Sudbury Regional Hospital. With Maureen Quigley he prepared the Report on Hospital Governance and Accountability in Ontario, for the OHA. In 2006-7 he served as independent Chair of the AHSC-AFP Task Force for the Physician’s Services Committee. In 2008 he was appointed as Investigator and subsequently Supervisor of the Kingston General Hospital and in 2009 as Supervisor of Quinte Health Care.
He serves as a mediator/facilitator between hospitals and physicians and does confidential assessments of non-profit and profit-based Boards and management teams.
Mr. Scott is Chair of the Board of the Canada Health Infoway, Chair of the Institute for Research on Public Policy and Vice Chair of OEB Enterprise and Mr. Scott is a Director of the Association of the Faculties of Medicine of Canada, The Ontario Institute For Cancer Research, the UNTD Association of Canada and Rothesay Netherwood School . He is on the Advisory board of Sanofi Pasteur Limited.
In 2005, he was appointed to the Order of Canada and is partner emeritus of McMillan LLP.
Vice-President, SickKids International
Cathy Seguin co-founded and was appointed Vice-President of SickKids International (SKI) in 2005. She leads SKI’s strategy, enabling SickKids to further its international leadership goals in patient care advisory, education and research.
Cathy has more than 25 years of hospital management experience, both in community and academic hospitals. At SickKids, she has held a number of leadership roles, including that of Vice-President of Child Health Services, Vice-President of Surgical Services and Professional Services, and Director of Diagnostic Imaging. Previous leadership roles have also extended to executive responsibility for Safe Kids Canada, a unit of SickKids until 2012.
Externally, Cathy has chaired the Ontario Paediatric Surgical Wait Times Expert Panel through the Wait Time Strategy at the Ministry of Health in 2006, as well as the Paediatric Subcommittee of the Critical Care Expert Advisory Panel in 2007. She was also Chair of the Provincial Council for Children’s Health Surgical Services Wait Time Task Force.
She holds a Master’s degree in business administration from The Richard Ivey School of Business. She is a member of the Canada Arab Business Council Board of Directors, and the Richard Ivey School of Business Health Sector Advisory Council. She is also former Chair of the Board of Directors for Parachute, a new national organization dedicated to injury prevention in Canada.
Shirlee M. Sharkey
President & CEO, Saint Elizabeth
CHE, MHSc, BScN, BA
Shirlee Sharkey is president and chief executive officer of Saint Elizabeth, a leading national health care organization known for its social innovation, strong financial performance and pioneering practices. As Canada’s largest social enterprise and vibrant not-for-profit innovator, Saint Elizabeth delivers more than six million health care visits annually and employs 8,000 people providing nursing, rehabilitation, personal support, research and consulting services. An organization firmly fixed on honouring human experiences in health care, Saint Elizabeth pursues innovative and exemplary practices to make a wider societal impact.
Shirlee’s commitment to community advancement is evident in her leadership and involvement on many boards, with a strong focus in innovation and health technology. Shirlee chairs the Ontario Health Technology Advisory Committee, and holds key leadership roles in the Canadian health innovation ecosystem including being a member of the Ontario Health Innovation Council, and a member of the Advisory Council of the International Centre for Health Innovation at the Ivey School of Business. Passionate about bringing new health technology to people more quickly, Shirlee serves on the EXCITE Management Board as well as EXCITE International where she collaborates worldwide to share ideas to strengthen the Canadian health system.
Academically, Shirlee is cross-appointed to the University of Toronto’s Lawrence S. Bloomberg Faculty of Nursing and the Institute of Health Policy, Management and Evaluation as an adjunct professor. She has appeared on a number of media panels and is widely published on home and community-based health care, health transformation, social innovation and breakthrough leadership. Shirlee is a sought-after speaker and a frequent contributor to The Globe and Mail.
Dean, Schulich School of Medicine & Dentistry
Distinguished University Professor, Western University
Dr. Michael J. Strong is Dean of the Schulich School of Medicine & Dentistry and Distinguished University Professor at Western University. He also holds the Arthur J. Hudson Chair in ALS Research. He undertook his undergraduate training in biochemistry and medicine at Queens University in Kingston (1976 – 1982), neurology training at Western University (1982 – 1987), and postgraduate training at the Laboratory of Central Nervous System Studies (director - D. Carleton Gadjusek, Nobel Laureate) at the National Institutes of Health, Bethesda, Maryland under the supervision of Ralph M. Garruto, PhD (1987 - 1990).
Dr. Strong is a scientist at the Robarts Research Institute, and served from 2000 to 2010 as the Chief of Neurology and Co-chair of the Department of Clinical Neurological Sciences at the London Health Sciences Centre and Western University. He has also served as Co-chair of the Canadian ALS Research Consortium and is a former member of the Board of Directors of the ALS Society of Canada. Dr. Strong is the lead investigator for the Ontario Neurodegenerative Research Institute (ONDRI), which received $28.5M in sponsorship funding from the Ontario Brain Institute.
Dr. Strong is the editor of the text “Amyotrophic Lateral Sclerosis and the Frontotemporal Dementias” (Oxford University Press, 2010), “Dementia and Motor Neuron Disease” (Taylor & Francis Press) co-editor with Professor Pamela Shaw of the text “Amyotrophic Lateral Sclerosis” (Blue Book Series). He has published over 160 peer-reviewed articles and 29 chapters, edited 4 textbooks and given over 120 invited lectures nationally and internationally related to his research in ALS.
Dr. Strong was awarded the Sheila Essay Award in 2005 and the Forbes Norris Award in 2008, and is the only Canadian to have received both international awards for ALS research. He was elected as a fellow of the American Academy of Neurology in 2008. In 2009, he was elected a Fellow of the Canadian Academy of Health Sciences.
His research has focused on understanding the cellular biology of ALS (Lou Gehrig’s disease) and has led to an understanding of the mechanisms by which intracellular deposits of protein (composed primarily of neurofilament) are formed, and how these aggregates contribute to the disease process of ALS. His research has also contributed to the understanding of neuropsychological deficits in ALS, both clinically and at the cellular level.
Paul Walker, M.D., Ph.D., F.R.C.S.C.
Director, President & Chief Executive Officer, Spectral Medical Inc.
Dr. Walker joined Spectral Medical Inc. (formerly Spectral Diagnostics Inc.) as President and CEO in April 2001. Previously, he held the position of COO of the Toronto General Hospital, and was Surgeon in Chief and Vice President of the Surgical Directorate of the University Hospital Network. Dr. Walker was an active Vascular Surgeon and the Director of the Intensive Care Program, and Professor of Medicine and Laboratory Medicine at the University of Toronto.
A pioneer in the area of endotoxin and its role in sepsis, and the co-inventor of the Endotoxin Activity Assay (EAA™). Dr. Walker is a frequent participant at leading sepsis and critical care conferences, has been a keynote speaker at symposiums focusing on the role of endotoxin in sepsis, and is the author of over 100 scientific publications. He received his M.D. from the University of Western Ontario, his Ph.D. from the Salgrenska University of Göteborg, Sweden, and is a graduate of the Advanced Management Program from Harvard School of Business.